BIOMARKER DISCOVERY IN GLUCOCORTICOID RESISTANCE IN EAE

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 目前，多发性硬化症(MS)还没有治愈方法。免疫抑制和 免疫调节治疗包括糖皮质激素(GC)用于治疗急性 多发性硬化症的发作和缓慢复发。然而，没有足够的生物标志物存在来表明 治疗效果和/或治疗耐药性的发展。因此，目标是 该项目旨在识别生物标志物，以监测免疫调节治疗是否 在多发性硬化症中是否有效和/或患者是否产生治疗耐药性。我们会 糖皮质激素治疗实验性自身免疫小鼠的研究 脑脊髓炎(EAE)作为MS的公认模型结合免疫学 用蛋白质组学方法研究，我们希望发现蛋白质(生物标记物) 指出GC治疗何时有效，并进一步提供我们关于 GC耐药机制的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Currently there is no cure for multiple sclerosis (MS). Immunosuppressive and immunomodulatory treatments including glucocorticoids (GC) are used to treat acute attacks of MS and slow relapses. However, no adequate biomarkers exist to show treatment efficacy and/or development of treatment resistance. Therefore, the goal of this project is to identify biomarkers to monitor whether immunomodulatory treatments in MS are effective and/or whether patients develop treatment resistance. We will study glucocorticoid (GC) treatment of mice with experimental autoimmune encephalomyelitis (EAE) as a generally accepted model of MS. Combining immunological studies with proteomics methods we expect to discover proteins (biomarkers) that indicate when the GC treatment is effective and furthermore provide us information on the mechanisms of GC resistance.